A method for monitoring the survival of highly active folic acid

Abstract

The present application relates to the technical field of folic acid activity monitoring, and in particular to a method for monitoring high-activity folic acid activity. The method includes: obtaining the physical condition information of the user, and determining the influence coefficient set based on the physical condition information; obtaining the blood test data of the user, determining the activity data reflected outward, and determining the real activity data based on the activity data reflected outward according to the influence coefficient set; obtaining the basic information of the user, and determining the basic standard of folic acid activity based on the basic information, and determining the final folic acid activity standard based on the basic standard of folic acid activity according to the influence coefficient set; comparing the real activity data with the final folic acid activity standard, and judging whether the difference between the real activity data and the final folic acid activity standard is within the preset difference range. If so, it is determined that the folic acid activity index in the user's body has reached the standard. The present application solves the problem that the existing technology cannot accurately monitor and judge the overall activity of high-activity folic acid in the user's body.

Description

Technical Field

[0001] The present application relates to the technical field of folic acid preservation monitoring, and in particular to a method for preserving high-activity folic acid. Background Art

[0002] Highly active folic acid refers to a form of folic acid that is more easily absorbed and utilized by the human body. It is also called methylfolate or 5-methyltetrahydrofolate. Drugs with highly active folic acid as the main ingredient are usually used for prenatal nutritional supplements for pregnant women, treatment of anemia patients, and folic acid supplementation for patients with folic acid absorption disorders.

[0003] Existing methods for monitoring the survival of highly active folic acid usually monitor the activity of highly active folic acid in drugs during drug production and factory testing stages, but are unable to monitor and determine the overall activity of highly active folic acid in the body of the user, resulting in the inability of the high folic acid activity monitoring results to accurately reflect the user's medication situation, causing poor treatment effects for the user. Summary of the invention

[0004] The present application provides a high-activity folic acid preservation monitoring method to solve the above-mentioned problems.

[0005] In a first aspect, the present application provides a method for monitoring the survival of high-activity folic acid, the method comprising:

[0006] Acquiring the physical condition information of the medication user, and determining, based on the physical condition information, a set of influence coefficients of the current physical condition of the medication user on the activity of folic acid;

[0007] Acquiring the blood test data of the user, determining the outwardly reflected activity data of folic acid in the user, and determining the real activity data of folic acid in the user based on the outwardly reflected activity data and the influence coefficient set;

[0008] Acquiring basic information of the drug user, determining a basic standard of folic acid activity based on the basic information, and determining a final folic acid activity standard of the drug user based on the basic standard of folic acid activity and the influence coefficient set;

[0009] The actual activity data is compared with the final folic acid activity standard, and based on the comparison result, it is determined whether the difference between the actual activity data and the final folic acid activity standard is within a preset difference range. If so, it is determined that the folic acid activity index in the user's body has reached the standard.

[0010] The method of the present application analyzes the specific physical condition of the user, extracts a set of influence coefficients that will affect the folic acid activity under the user's current physical condition, namely, the influence coefficient set, and adjusts the folic acid activity data in the user's blood according to the influence coefficient set to obtain true folic acid activity data that conforms to the user's overall physical condition. At the same time, the basic folic acid standard that conforms to the user's basic information is adjusted according to the influence coefficient set to obtain the final folic acid activity standard that can be used to measure the user's current overall physical condition. By analyzing the degree of difference between the above-mentioned user's true folic acid activity data and the final folic acid activity standard, it is possible to accurately monitor and judge whether the user's current folic acid activity meets the standard, thereby solving the problem that the prior art cannot accurately monitor and judge the overall activity of high-activity folic acid in the user's body.

[0011] Optionally, the physical condition information includes but is not limited to AST value and ALT value, and determining the influence coefficient set of the current physical condition of the user on folic acid activity based on the physical condition information includes:

[0012] The AST value and the ALT value are compared with a preset normal liver function data range, and if at least one of the AST value and the ALT value is outside the preset normal liver function data range, the liver function influence coefficient of the user's liver function on the folic acid activity is included in the influence coefficient set;

[0013] According to the AST value and the ALT value, the liver function influence coefficient is calculated with reference to the following formula:

[0014] ;

[0015] in, is the liver function influence coefficient, The influence ratio of the preset AST value is: The influence ratio of the preset ALT value.

[0016] According to the above technical scheme, when the user has abnormal liver function, the influence coefficient of the user's current liver function on folic acid activity is calculated based on the AST value and the ALT value, which are two data that will have a significant impact on the folic acid activity in the human body, so that the calculated liver function influence coefficient is highly consistent with the user's specific liver function conditions, so that in the case of abnormal liver function of the user, the real activity data taking the user's liver function into consideration can be obtained later, thereby making the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0017] Optionally, the physical condition information further includes a GFR value and a UAE value, and determining, based on the physical condition information, a set of influence coefficients of the user's current physical condition on folic acid activity, including:

[0018] The GFR value and the UAE value are compared with a preset normal renal function data range. If at least one of the GFR value and the UAE value is outside the preset normal renal function data range, the renal function influence coefficient of the user's renal function on the folic acid activity is included in the influence coefficient set as the influence coefficient;

[0019] According to the GFR value and the UAE value, the renal function influence coefficient is calculated with reference to the following formula:

[0020] ;

[0021] in, is the renal function influence coefficient, The influence ratio of preset GFR value is The impact ratio of the preset UAE value.

[0022] According to the above technical scheme, when the user has abnormal renal function, the influence coefficient of the user's current renal function on folic acid activity is calculated based on the GFR value and UAE value, two data that will have a significant impact on the folic acid activity in the human body, so that the calculated renal function influence coefficient is highly consistent with the user's specific renal function conditions, so that in the case of abnormal renal function of the user, the real activity data taking the user's renal function into consideration can be obtained subsequently, and the final judgment of the folic acid activity in the user's body is further made more accurate and comprehensive.

[0023] Optionally, the physical condition information further includes a GAC ​​value and a GAPH value, and determining, based on the physical condition information, a set of influence coefficients of the user's current physical condition on folic acid activity, includes:

[0024] The GAC value and the GAPH value are compared with a preset normal gastric function data range, and if at least one of the GAC value and the GAPH value is outside the preset normal gastric function data range, the gastric function influence coefficient of the gastric function of the user on the folic acid activity is included in the influence coefficient set as the influence coefficient;

[0025] According to the GAC value and the GAPH value, the gastric function influence coefficient is calculated with reference to the following formula:

[0026] ;

[0027] in, is the gastric function influence coefficient, The impact ratio of the preset GAC value is: It is the influence ratio of preset GAPH value.

[0028] According to the above technical scheme, when the user has abnormal gastric function, the influence coefficient of the user's current gastric function on folic acid activity is calculated based on the GAC value and the GAPH value, which are data that will have a significant impact on the folic acid activity in the human body, so that the calculated gastric function influence coefficient is highly consistent with the user's specific gastric function conditions, so that in the case of abnormal gastric function of the user, the real activity data taking the user's gastric function into consideration can be obtained subsequently, thereby making the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0029] Optionally, the physical condition information further includes a PDA value and an IPH value, and determining, based on the physical condition information, a set of influence coefficients of the user's current physical condition on folic acid activity, includes:

[0030] The PDA value and the IPH value are compared with a preset normal intestinal function data range. If at least one of the PDA value and the IPH value is outside the preset normal intestinal function data range, the intestinal function influence coefficient of the intestinal function of the user on the folic acid activity is included in the influence coefficient set as the influence coefficient;

[0031] According to the PDA value and the IPH value, the intestinal function influence coefficient is calculated with reference to the following formula:

[0032] ;

[0033] in, is the intestinal function influence coefficient, is the influence ratio of preset PDA value, It is the impact ratio of preset IPH value.

[0034] According to the above technical scheme, when the intestinal function of the drug user is abnormal, the influence coefficient of the current intestinal function of the drug user on the folic acid activity is calculated based on the PDA value and the IPH value, which are two data that will have a significant impact on the folic acid activity in the human body, so that the calculated intestinal function influence coefficient is highly consistent with the specific intestinal function of the drug user, so that in the case of abnormal intestinal function of the drug user, the real activity data taking the intestinal function of the drug user into consideration can be obtained subsequently, and the final judgment of the folic acid activity in the drug user's body can be further more accurate and comprehensive.

[0035] Optionally, the physical condition information further includes a BMR value and a UAL value, and determining, based on the physical condition information, a set of influence coefficients of the user's current physical condition on folic acid activity, including:

[0036] The BMR value and the UAL value are compared with a preset normal metabolic function data range. If at least one of the BMR value and the UAL value is outside the preset normal metabolic function data range, the metabolic function influence coefficient of the user's metabolic function on the folic acid activity is included in the influence coefficient set as the influence coefficient;

[0037] According to the BMR value and the UAL value, the metabolic function influence coefficient is calculated with reference to the following formula:

[0038] ;

[0039] in, is the metabolic function influence coefficient, The influence ratio of preset BMR value, The impact ratio of the preset UAL value.

[0040] According to the above technical scheme, when the metabolic function of the drug user is abnormal, the influence coefficient of the current metabolic function of the drug user on the folic acid activity is calculated based on the BMR value and the UAL value, which are two data that will have a significant impact on the folic acid activity in the human body, so that the calculated metabolic function influence coefficient is highly consistent with the specific metabolic function of the drug user, so that in the case of abnormal metabolic function of the drug user, the real activity data taking the metabolic function of the drug user into consideration can be obtained later, and the final judgment of the folic acid activity in the drug user's body is further more accurate and comprehensive.

[0041] Optionally, the physical condition information also includes medical history information of the user, and determining, based on the physical condition information, a set of influence coefficients of the user's current physical condition on folic acid activity, includes:

[0042] Determining the long-term medication information of the medication user according to the medical history information of the medication user;

[0043] Matching the long-term medication information with the drug data affecting folic acid activity in the preset drug impact data set, and if the match is successful, determining the influencing drug information according to the matching result, and including the total drug impact coefficient of the user's medication situation on the folic acid activity into the impact coefficient set;

[0044] Determine, based on the influencing drug information, the time difference between the dosage and the taking time of each influencing drug and the monitoring time;

[0045] Determining the total drug impact coefficient according to the dosage and the time difference;

[0046] The total drug impact coefficient is determined based on the dosage and the time difference, and is calculated by referring to the following formula:

[0047] ;

[0048] in, is the total drug effect coefficient, For each of the affected drugs, For the the dose of the drug that affects the is the time difference.

[0049] The above technical scheme calculates the total drug impact coefficient based on the dosage of each influencing drug and the time difference between taking the drug and the monitoring time when the user uses other drugs that affect folic acid activity, so that the total drug impact coefficient is highly consistent with the user's medication situation, so that when the user uses other drugs that affect folic acid activity, the real activity data taking the user's medication situation into consideration can be obtained later, further making the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0050] Optionally, the determining the real activity data of folic acid in the user based on the outwardly reflected activity data and according to the influence coefficient set includes:

[0051] According to the influence coefficient set, an influence weight of each influence coefficient in the influence coefficient set is determined.

[0052] Based on the outwardly reflected activity data, according to the influence coefficient set, the real activity data of folic acid in the body of the user is determined, and calculated with reference to the following formula:

[0053] ;

[0054] in, is the real activity data, is the number of influence coefficients in the influence coefficient set, For the activity data reflected externally, is the first The influence coefficient, The first The influence weight of an influence coefficient.

[0055] The above technical scheme calculates the real activity data based on the activity data reflected externally, according to the influence coefficient corresponding to the physical condition of the user and the influence weight corresponding to the influence coefficient, so that the real activity data is highly consistent with the current physical condition of the user, and thus the real activity data is more representative in reflecting the overall folic acid activity in the body of the user, providing an important data basis for the subsequent judgment of the overall folic acid activity of the user.

[0056] Optionally, determining the basic standard of folic acid activity based on the basic information, and determining the final folic acid activity standard of the user based on the basic standard of folic acid activity and the influence coefficient, includes:

[0057] Determining a standard metabolic rate based on the basic information;

[0058] Determining the folic acid activity standard according to the basic information and the standard metabolic rate;

[0059] The folic acid activity standard is determined based on the basic information and the standard metabolic rate, and is calculated by referring to the following formula:

[0060] ;

[0061] in, is the basic standard of folic acid activity, is the coefficient of relationship between standard metabolic rate and folic acid activity, is the standard metabolic rate;

[0062] Based on the basic folate activity standard and according to the influence coefficient set, the final folate activity standard is calculated by the following formula:

[0063] ;

[0064] in is the final folic acid activity standard, is the basic standard of folic acid activity, is the first An influence coefficient.

[0065] The above technical scheme calculates the final folic acid activity standard according to the influence coefficients in the influence coefficient set and the influence weights corresponding to each influence coefficient, based on the basic standard of folic acid activity, and fully considers that when the user has physical abnormalities, the standard for judging the activity of folic acid in his body should also be adjusted accordingly, so that the adjusted final folic acid activity standard is highly consistent with the user's current physical condition, thereby making the judgment of the overall folic acid activity in the user's body more accurate and comprehensive.

[0066] Optionally, the method further includes:

[0067] If the folic acid activity index in the user does not meet the standard, determining the activity difference value according to the actual activity data and the final folic acid activity standard;

[0068] Obtaining the dosage of the high-activity folic acid drug taken by the user before monitoring, and determining the drug utilization rate of the user according to the dosage of the high-activity folic acid drug and the real activity data;

[0069] The drug utilization rate of the user is determined based on the dosage of the high-activity folic acid drug and the real activity data, and is calculated by referring to the following formula:

[0070] ;

[0071] in, is the drug utilization rate, is the real activity data, The dosage of the high-activity folic acid drug taken by the user before monitoring;

[0072] determining a supplemental drug dosage according to the activity difference value and the drug utilization rate;

[0073] The supplementary drug dosage is determined based on the activity difference value and the drug utilization rate, and is calculated by referring to the following formula:

[0074] ;

[0075] in, For the supplemental drug dosage, is the activity difference value, is the utilization rate of the drug;

[0076] The user is given drug supplement according to the supplementary drug dosage.

[0077] The above technical scheme, when the folic acid activity index in the body of the drug user does not meet the standard, obtains the dosage of high-folate activity drug that the drug user needs to supplement based on the difference between the actual activity data and the final folic acid activity standard, combined with the drug utilization rate of the drug user, so as to meet the standard folic acid activity in the body of the drug user and ensure the treatment effect of the drug user. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, a brief introduction will be given below to the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0079] Figure 1 A schematic diagram of an application scenario provided for an embodiment of the present application;

[0080] Figure 2 This is a flow chart of a method for monitoring the survival of highly active folic acid provided in one embodiment of the present application. DETAILED DESCRIPTION

[0081] In order to make the purpose, technical scheme and advantages of the embodiments of the present application clearer, the technical scheme in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0082] In addition, the term "and / or" in this article is only a description of the association relationship of associated objects, indicating that there can be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. In addition, the character " / " in this article, unless otherwise specified, generally means that the associated objects before and after are in an "or" relationship.

[0083] The embodiments of the present application are further described in detail below in conjunction with the drawings in the specification.

[0084] Existing methods for monitoring the survival of highly active folic acid usually monitor the activity of highly active folic acid in drugs during drug production and factory testing stages, but are unable to monitor and determine the overall activity of highly active folic acid in the body of the user, resulting in the inability of the high folic acid activity monitoring results to accurately reflect the patient's medication situation, causing poor treatment effects for the user.

[0085] Based on this, the present application provides a high-activity folic acid maintenance monitoring method, which analyzes the specific physical condition of the user, extracts a set of influence coefficients that will affect the folic acid activity under the user's current physical condition, that is, the influence coefficient set, and adjusts the folic acid activity data in the user's blood according to the influence coefficient set to obtain true folic acid activity data that conforms to the user's overall physical condition. At the same time, the basic folic acid standard that conforms to the user's basic information is adjusted according to the influence coefficient set to obtain the final folic acid activity standard that can be used to measure the user's current overall physical condition. By analyzing the degree of difference between the above-mentioned user's true folic acid activity data and the final folic acid activity standard, it is possible to accurately monitor and judge whether the user's current folic acid activity in the body meets the standard.

[0086] Figure 1 A schematic diagram of an application scenario provided for the present application. When monitoring the folic acid activity in the body of a user, the method of the present application is applied to monitor and judge the folic acid activity of high-activity folic acid drugs in the body of the user according to the specific physical condition of the user, thereby improving the accuracy of the monitoring results of folic acid activity in the body of the user.

[0087] The monitoring device using the method of the present application includes several medical examination equipment and a server installed in a hospital and capable of interacting with a hospital information system, and the method of the present application is installed in the server.

[0088] Specifically, the user is examined by several medical examination equipment, and the blood test data, physical condition information and basic information obtained from the examination are transmitted to the server. The server obtains the activity data reflected outward based on the blood test data, and then obtains the influence coefficient set that affects the folic acid activity in the user's body based on the physical condition information and the user's medical history information. The server obtains the real activity data and the final folic acid activity standard that meet the user's physical condition based on the influence coefficient set. Finally, the server compares the real activity data with the final folic acid activity standard, and determines whether the folic acid activity index in the user's body meets the standard based on the comparison result, so as to solve the problem that the existing technology cannot accurately monitor and judge the overall activity of high-activity folic acid in the user's body, so that the monitoring results can accurately reflect the user's medication situation and improve the treatment effect of the user. The specific implementation method can refer to the following embodiments.

[0089] Figure 2 This is a flow chart of a high-activity folic acid maintenance monitoring method provided in an embodiment of the present application. The method of this embodiment can be applied to the server in the above scenario. Figure 2 As shown, the method includes:

[0090] S201. Obtain the physical condition information of the medication user, and determine, based on the physical condition information, a set of influence coefficients of the current physical condition of the medication user on the activity of folic acid.

[0091] The users may be those who use highly active folic acid medicines.

[0092] The physical condition information may be a series of medical indicator information reflecting the physical condition of the medication user.

[0093] Folic acid activity may refer to the activity of high-activity folic acid in high-activity folic acid medicines in the human body.

[0094] The influence coefficient set may be a collection of a series of influence coefficients that may affect the activity of high-activity folic acid in the user's physical condition.

[0095] Specifically, the physical condition of the drug user will have a direct impact on the activity of folic acid in his body, which in turn affects the accuracy of the monitoring results of folic acid activity in the drug user, resulting in the medical staff or the drug user themselves being unable to accurately grasp the medication situation, and unable to accurately know the effectiveness of the current high-activity folic acid drug for the drug user, resulting in less than ideal treatment effects for the drug user. Therefore, it is necessary to extract the medical indicators that will affect the folic acid activity in the user's current physical condition information based on the user's physical condition, and then extract the influence coefficients of the above medical indicators on folic acid activity, and include the above influence coefficients in the influence coefficient set, so as to provide a basis for obtaining accurate folic acid activity data based on the user's physical condition in the future.

[0096] S202, obtaining blood test data of the medication user, determining the outwardly reflected activity data of folic acid in the medication user, and determining the real activity data of folic acid in the medication user based on the outwardly reflected activity data and a set of influence coefficients.

[0097] The blood test data may be a series of data reflecting the blood condition of the medication user, including but not limited to the folic acid activity data, the number of white blood cells and the number of red blood cells in the medication user's blood.

[0098] The activity data reflected externally may be the folic acid activity data in the blood of the user.

[0099] The real activity data may be folic acid activity data that reflects the overall folic acid activity in the body of the user.

[0100] Specifically, the existing technology for monitoring the folic acid activity in the body of a drug user usually involves drawing blood from the drug user and detecting the folic acid activity in the drug user's blood to obtain folic acid activity data. However, the folic acid activity data in the drug user's blood obtained in the above manner mainly reflects the transportation and metabolism of folic acid in the drug user's body, and cannot represent the overall folic acid activity in the drug user's body. Therefore, it is necessary to consider the impact of the conditions in other parts of the patient's body on the folic acid activity based on the folic acid activity data in the drug user's blood, so as to obtain real folic acid activity data that can accurately reflect the overall folic acid activity in the drug user, thereby providing important data basis for subsequent judgment on whether the folic acid activity in the drug user meets the standard.

[0101] S203. Obtain basic information of the drug user, determine a basic standard of folic acid activity based on the basic information, and determine a final standard of folic acid activity for the drug user based on the basic standard of folic acid activity and a set of influence coefficients.

[0102] Basic information includes but is not limited to the user's gender, height, weight and age.

[0103] The basic standard of folic acid activity may be the standard data of folic acid activity of a normal person corresponding to the basic information of the user.

[0104] The final folic acid activity standard may be the folic acid activity standard data that is obtained after taking the specific physical condition of the user into consideration and that is in accordance with the user's current condition.

[0105] Specifically, when the user has other physical conditions, such as disease in some of the user's internal organs, the folic acid activity standard in a normal human body cannot be used as a standard to measure whether the user's actual activity data meets the standard. The user's specific physical condition needs to be taken into consideration in the folic acid activity standard formulation process, and the basic folic acid activity standard that meets the user's basic information needs to be adjusted to obtain the final folic acid activity standard that meets the user's current status, so that the judgment of the folic acid activity in the user's body is more in line with the user's specific situation.

[0106] S204. Compare the actual activity data with the final folic acid activity standard, and determine whether the difference between the actual activity data and the final folic acid activity standard is within a preset difference range based on the comparison result. If so, it is determined that the folic acid activity index in the user's body has reached the standard.

[0107] The preset difference range can be a safe difference range between the actual activity data and the final folic acid activity standard, and the preset difference range can be obtained through statistics of historical medical clinical data.

[0108] Specifically, after obtaining the actual activity data and the final folic acid activity standard, the above two data are compared to obtain the difference. If the difference is within the preset difference range, it means that the folic acid activity in the body of the user is within the normal range at this time, which can further indicate that the high-activity folic acid drug and dosage used by the current user are in line with the user's current physical condition.

[0109] The method of the present application analyzes the specific physical condition of the user, extracts a set of influence coefficients that will affect the folic acid activity under the user's current physical condition, namely, the influence coefficient set, and adjusts the folic acid activity data in the user's blood according to the influence coefficient set to obtain true folic acid activity data that conforms to the user's overall physical condition. At the same time, the basic folic acid standard that conforms to the user's basic information is adjusted according to the influence coefficient set to obtain the final folic acid activity standard that can be used to measure the user's current overall physical condition. By analyzing the degree of difference between the above-mentioned user's true folic acid activity data and the final folic acid activity standard, it is possible to accurately monitor and judge whether the user's current folic acid activity meets the standard, thereby solving the problem that the prior art cannot accurately monitor and judge the overall activity of high-activity folic acid in the user's body.

[0110] In some embodiments, the AST value and the ALT value are compared with a preset normal liver function data range. If at least one of the AST value and the ALT value is outside the preset normal liver function data range, the liver function influence coefficient of the user's liver function on folic acid activity is included in the influence coefficient set; based on the AST value and the ALT value, the liver function influence coefficient is calculated according to the reference formula (1):

[0111] (1);

[0112] in, is the liver function influence coefficient, The influence ratio of the preset AST value is: The influence ratio of the preset ALT value.

[0113] The AST value (Aspartate Aminotransferase) can be a numerical value that reflects the level of alanine aminotransferase in the body of the user.

[0114] The ALT value (Alanine Aminotransferase) can be a numerical value that reflects the level of aspartate aminotransferase in the body of the user.

[0115] Both AST and ALT values ​​can be obtained by examining the user through existing medical liver function testing equipment.

[0116] The preset normal liver function data range may be a data range of a series of liver function indicators of a medically normal person, which may be obtained through statistics of historical medical clinical data, including but not limited to an AST value range and an ALT value range.

[0117] The preset AST value influence ratio can be set to 15%~30%, and can also be adjusted according to the specific situation of the user. This application does not make specific limitations.

[0118] The preset ALT value influence ratio can be set to 70% to 85%, and can also be adjusted according to the specific situation of the user. This application does not make any specific limitation.

[0119] It should be noted that ALT mainly exists in liver cells. When the liver is damaged, ALT is released into the blood. The level of ALT value directly reflects the functional status of the liver. Although AST is also closely related to liver function, abnormalities in other parts of the patient may also cause the AST value to be too high. Therefore, when setting and adjusting the preset AST value impact ratio and the preset ALT value impact ratio, the ALT value impact ratio should be significantly higher than the AST value impact ratio.

[0120] Specifically, abnormal AST and ALT values ​​usually mean that the user's liver is damaged or diseased, and the condition of liver function in the human body will directly and significantly affect the drug absorption rate in the human body. The liver affects the concentration and effect of high-activity folic acid drugs in the user's body through metabolism and conversion, and indirectly affects the activity of folic acid in the user's body. Therefore, when at least one of the AST and ALT values ​​is outside the preset normal liver function data range, it means that the user's liver function is abnormal. At this time, the folic acid activity in the user's body will be significantly affected by the user's liver function. Therefore, it is necessary to include the influence coefficient of the user's current liver function on folic acid activity into the influence coefficient set, so that the subsequent actual activity data will include consideration of the impact of the user's abnormal liver function.

[0121] It should be noted that when at least one of the AST value and the ALT value is outside the preset normal liver function data range, but at least one of the values ​​is within the preset normal liver function data range, it means that at this time, one of the above two values ​​has a significant effect on the folic acid activity in the body of the drug user, while the effect of the other value on the folic acid activity is within the normal range. In this case, it is necessary to increase the influence ratio of the value outside the preset normal liver function data range based on its corresponding preset influence ratio. The specific increase range is determined according to the difference between the value and the preset normal liver function data range, so that the liver function influence coefficient calculated by formula (2) is more in line with the specific liver function condition of the drug user.

[0122] In the method of this embodiment, when the user has abnormal liver function, the influence coefficient of the user's current liver function on folic acid activity is calculated based on the AST value and the ALT value, which are data that will have a significant impact on the folic acid activity in the human body. At the same time, by introducing and adjusting the influence ratio of the AST value and the ALT value, the calculated liver function influence coefficient is made to be highly consistent with the specific liver function of the user, so that in the case of abnormal liver function of the user, the real activity data taking the user's liver function into consideration can be obtained later, thereby making the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0123] The GFR value and the UAE value are compared with the preset normal renal function data range. If at least one of the GFR value and the UAE value is outside the preset normal renal function data range, the renal function influence coefficient of the user's renal function on folic acid activity is included in the influence coefficient set as the influence coefficient; based on the GFR value and the UAE value, the renal function influence coefficient is calculated according to the reference formula (2):

[0124] (2);

[0125] in, is the renal function influence coefficient, The influence ratio of preset GFR value is The impact ratio of the preset UAE value.

[0126] The GFR value (Glomerular Filtration Rate) can be a numerical value that reflects the glomerular filtration rate of the user.

[0127] The UAE value (Uric Acid Excretion) can be a numerical value that reflects the uric acid excretion rate of the user.

[0128] Both GFR and UAE values ​​can be obtained by examining the user through existing medical renal function testing equipment.

[0129] The preset GFR value influence ratio can be set to 60%~70%, which can be adjusted according to the specific situation of the user, and this application does not make specific limitations.

[0130] The preset UAE value impact ratio can be set to 30%~40%, which can be adjusted according to the specific situation of the user, and this application does not make specific limitations.

[0131] It should be noted that the GFR value directly reflects whether the kidney's filtering function of various substances in the blood is normal. Therefore, when setting and adjusting the preset GFR value impact ratio and the preset UAE value impact ratio, the GFR value impact ratio should be significantly higher than the UAE value impact ratio.

[0132] The preset normal liver function data range may be a data range of a series of renal function indicators of medically normal people, which may be obtained through statistics of historical medical clinical data, including but not limited to an AST value range and an ALT value range.

[0133] Specifically, abnormal GFR and UAE values ​​indicate that the user has abnormal renal function. When the user's GFR value is abnormal, the user's body cannot effectively eliminate metabolites, resulting in metabolic disorders in the user, thereby affecting the metabolism, utilization and activity of folic acid. When the user's UAE value is abnormal, the activity of enzymes in the user's body becomes abnormal, resulting in abnormal folic acid metabolism, which in turn affects folic acid activity. Therefore, when at least one of the GFR and UAE values ​​is outside the preset normal renal function data range, the folic acid activity in the user's body will be affected by the user's current renal function. Therefore, it is necessary to include the influence coefficient of the user's current renal function on folic acid activity into the influence coefficient set, so that the subsequent actual activity data includes consideration of the impact of the user's abnormal renal function.

[0134] It should be noted that when at least one of the GFR value and the UAE value is outside the preset normal renal function data range, but at least one of the values ​​is within the preset normal renal function data range, it means that at this time, one of the above two values ​​has a significant effect on the folic acid activity in the body of the user, while the effect of the other value on the folic acid activity is within the normal range. In this case, it is necessary to increase the influence ratio of the value outside the preset normal renal function data range based on its corresponding preset influence ratio. The specific increase range is determined according to the difference between the value and the preset normal renal function data range, so that the renal function influence coefficient calculated by formula (3) is more in line with the specific renal function condition of the user.

[0135] In the method of this embodiment, when the user has abnormal renal function, the influence coefficient of the user's current renal function on folic acid activity is calculated based on the GFR value and UAE value, which are data that will have a significant impact on the folic acid activity in the human body. At the same time, by introducing and adjusting the influence ratio of the GFR value and the UAE value, the calculated renal function influence coefficient is made to be highly consistent with the specific renal function of the user, so that in the case of abnormal renal function of the user, the real activity data taking the user's renal function into consideration can be obtained later, which further makes the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0136] In some embodiments, the GAC value and the GAPH value are compared with a preset normal gastric function data range. If at least one of the GAC value and the GAPH value is outside the preset normal gastric function data range, the gastric function influence coefficient of the gastric function of the user on the folic acid activity is included in the influence coefficient set as an influence coefficient; based on the GAC value and the GAPH value, the gastric function influence coefficient is calculated according to the reference formula (3):

[0137] (3);

[0138] in, is the gastric function influence coefficient, The impact ratio of the preset GAC value is: It is the influence ratio of preset GAPH value.

[0139] The GAC value (Gastric Acid Concentration) may be data reflecting the gastric acid concentration of the medication user.

[0140] The GAPH value (Gastric Acid pH) may be data reflecting the gastric acid pH of a medication user.

[0141] Both GAC value and GAPH value can be obtained by examining the user through existing medical gastric function examination equipment.

[0142] The preset GAC value influence ratio can be set to 70%~80%, and can also be adjusted according to the specific situation of the user. This application does not make specific limitations.

[0143] The preset GAPH value influence ratio can be set to 20%~30%, and can also be adjusted according to the specific situation of the user. This application does not make specific limitations.

[0144] It should be noted that gastric acid is a strong acid, the main component of which is hydrochloric acid. The higher the GAC value, the more hydrochloric acid is contained in the user's gastric juice, and the stronger the acidity. When the gastric acid concentration is higher, the absorption and utilization efficiency of folic acid in the body can be increased, thereby improving the active state of folic acid. The GAPH value usually only reflects the characteristics of gastric acid. Therefore, when setting and adjusting the preset GAC value impact ratio and the preset GAPH value impact ratio, the GAC value impact ratio should be significantly higher than the GAPH value impact ratio.

[0145] Specifically, when the GAC value and the GAPH value are abnormal, it means that the user has abnormal gastric function, which in turn means that the user cannot effectively absorb and utilize high-activity folic acid drugs. Therefore, when at least one of the GAC value and the GAPH value is outside the preset normal gastric function data range, the folic acid activity in the user's body will be affected by the user's current gastric function. Therefore, it is necessary to include the influence coefficient of the user's current gastric function on folic acid activity into the influence coefficient set, so that the actual activity data obtained subsequently includes consideration of the impact on the user's abnormal gastric function.

[0146] It should be noted that when at least one of the GAC value and the GAPH value is outside the preset normal gastric function data range, but at least one of the values ​​is within the preset normal gastric function data range, it means that at this time, one of the above two values ​​has a significant effect on the folic acid activity in the body of the user, while the effect of the other value on the folic acid activity is within the normal range. In this case, it is necessary to increase the influence ratio of the value outside the preset normal gastric function data range based on its corresponding preset influence ratio. The specific increase range is determined according to the difference between the value and the preset normal gastric function data range, so that the gastric function influence coefficient calculated by formula (4) is more in line with the specific gastric function of the user.

[0147] In the method of this embodiment, when the user has abnormal gastric function, the influence coefficient of the user's current gastric function on folic acid activity is calculated based on the GAC value and the GAPH value, which are data that will have a significant impact on the folic acid activity in the human body. At the same time, by introducing and adjusting the influence ratio of the GAC value and the GAPH value, the calculated gastric function influence coefficient is made to be highly consistent with the user's specific gastric function. In the case of abnormal gastric function of the user, the real activity data taking the user's gastric function into consideration can be obtained later, which further makes the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0148] In some embodiments, the PDA value and the IPH value are compared with a preset normal intestinal function data range. If at least one of the PDA value and the IPH value is outside the preset normal intestinal function data range, the intestinal function influence coefficient of the intestinal function of the user on the folic acid activity is included in the influence coefficient set as an influence coefficient; based on the PDA value and the IPH value, the calculation reference formula (4) for the intestinal function influence coefficient is:

[0149] (4);

[0150] in, is the intestinal function influence coefficient, is the influence ratio of preset PDA value, It is the impact ratio of preset IPH value.

[0151] The PDA value (Pancreatic Digestive Enzymes) can be data used to reflect the activity of intestinal digestive enzymes in the user's body.

[0152] The IPH value (Intestinal pH) can be data used to reflect the pH value of the intestinal digestive fluid in the user's body.

[0153] Both PDA value and IPH value can be obtained by examining the user through existing medical intestinal function examination equipment.

[0154] The preset PDA value influence ratio can be set to 50%~60%, and can also be adjusted according to the specific situation of the user. This application does not make specific limitations.

[0155] The preset IPH value influence ratio can be set to 40%~50%, and can also be adjusted according to the specific situation of the user. This application does not make specific limitations.

[0156] It should be noted that intestinal digestive enzymes such as trypsin can help break down folic acid and its various forms, which can directly affect the absorption and utilization of folic acid. Changes in intestinal pH will affect the stability and solubility of folic acid, and indirectly affect the absorption and utilization efficiency of folic acid. Therefore, when setting and adjusting the preset PDA value impact ratio and the preset IPH value impact ratio, the PDA value impact ratio should be slightly higher than the IPH value impact ratio.

[0157] Specifically, when the PDA value and IPH value are abnormal, it means that the intestinal function of the user is abnormal, and further indicates that the user has abnormal absorption and utilization of high-activity folic acid drugs. Therefore, when at least one of the PDA value and the IPH value is outside the preset normal intestinal function data range, the folic acid activity in the user's body will be affected by the user's current intestinal function. Therefore, it is necessary to include the influence coefficient of the user's current intestinal function on folic acid activity into the influence coefficient set, so that the actual activity data obtained subsequently includes consideration of the impact on the user's abnormal intestinal function.

[0158] In the method of this embodiment, when the intestinal function of the user is abnormal, the influence coefficient of the user's current intestinal function on folic acid activity is calculated based on the PDA value and the IPH value, which are data that will have a significant impact on the folic acid activity in the human body. At the same time, by introducing and adjusting the influence ratio of the PDA value and the IPH value, the calculated intestinal function influence coefficient is made to be highly consistent with the specific intestinal function of the user, so that in the case of abnormal intestinal function of the user, the real activity data taking the intestinal function of the user into consideration can be obtained later, which further makes the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0159] In some embodiments, the BMR value and the UAL value are compared with a preset normal metabolic function data range. If at least one of the BMR value and the UAL value is outside the preset normal metabolic function data range, the metabolic function influence coefficient of the user's metabolic function on folic acid activity is included in the influence coefficient set as an influence coefficient; based on the BMR value and the UAL value, the metabolic function influence coefficient is calculated according to formula (5):

[0160] (5);

[0161] in, is the metabolic function influence coefficient, The influence ratio of preset BMR value, The impact ratio of the preset UAL value.

[0162] The BMR value (Basal Metabolic Rate) can be data reflecting the basal metabolic capacity of the user.

[0163] The UAL value (Uric Acid Level) can be data that reflects the level of uric acid in the body of the user.

[0164] Both BMR and UAL values ​​can be obtained by examining the user through existing medical metabolic function testing equipment.

[0165] The preset BMR value influence ratio can be set to 30%~40%, and can also be adjusted according to the specific situation of the user. This application does not make specific limitations.

[0166] The preset UAL value influence ratio can be set to 60%~70%, and can also be adjusted according to the specific situation of the user. This application does not make specific limitations.

[0167] It should be noted that uric acid is a product of purine metabolism. High uric acid levels will have a certain impact on the metabolism and utilization of folic acid, including competitive inhibition, destruction of folic acid structure, and reduced folic acid recycling. The basal metabolic rate refers to the energy consumption required to maintain basic life activities when the user is in a quiet state. Users with a higher basal metabolic rate will also have a relatively higher demand for folic acid. Therefore, when setting and adjusting the preset BMR value impact ratio and the preset UAL value impact ratio, the UAL value impact ratio should be significantly higher than the BMR value impact ratio.

[0168] Specifically, when the BMR value and the UAL value are abnormal, it indicates that the user's metabolic function is abnormal, resulting in an increased demand for folic acid or a decreased ability to absorb and utilize folic acid, thereby affecting the activity of folic acid. When at least one of the BMR value and the UAL value is outside the preset normal metabolic function data range, the folic acid activity in the user's body will be affected by the user's current metabolic function. Therefore, it is necessary to include the influence coefficient of the user's current metabolic function on folic acid activity into the influence coefficient set, so that the actual activity data obtained subsequently includes consideration of the impact on the user's abnormal metabolic function.

[0169] In the method of this embodiment, when the metabolic function of the user is abnormal, the influence coefficient of the user's current metabolic function on the folic acid activity is calculated based on the BMR value and the UAL value, which are data that will have a significant impact on the folic acid activity in the human body. At the same time, by introducing and adjusting the influence ratio of the BMR value and the UAL value, the calculated metabolic function influence coefficient is made to be highly consistent with the specific metabolic function of the user, so that in the case of abnormal metabolic function of the user, the real activity data taking the metabolic function of the user into consideration can be obtained later, which further makes the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0170] In some embodiments, the long-term medication information of the medication user is determined based on the medical history information of the medication user; the long-term medication information is matched with the drug data that affects folic acid activity in the preset drug impact data set. If the match is successful, the influencing drug information is determined based on the matching result, and the total drug impact coefficient of the medication situation of the medication user on folic acid activity is included in the impact coefficient set; based on the influencing drug information, the dosage of each influencing drug and the time difference between the taking time and the monitoring time are determined; based on the dosage and time difference, the total drug impact coefficient is determined; based on the dosage and time difference, the total drug impact coefficient is determined, and the reference formula (6) is used to calculate:

[0171] (6);

[0172] in, is the total drug effect coefficient, For each of the affected drugs, For the the dose of the drug that affects the is the time difference.

[0173] The medical history information of the drug user may be the drug user's long-term historical disease and treatment information, and the drug user's medical history information may be obtained through the drug user's medical history information or paper medical record information.

[0174] Long-term medication information may be information about medications that a user has taken for a long time, and the long-term medication information may be obtained through oral description by the user or through the user's medical history information.

[0175] The preset drug impact data set may be an information set of drugs that may affect folic acid activity, and the preset drug impact data set may be obtained through experimental data.

[0176] The influencing drug information may be the drug information taken by the user that may affect the folic acid activity in the high-folate drug. The influencing drug information includes but is not limited to the drug dosage and the drug taking time.

[0177] Specifically, the overall folic acid activity in the body of the user is not only affected by the conditions of various parts of the user's body mentioned in the aforementioned embodiments, but also by other drugs taken by the user during the period of taking high-folate activity drugs, such as anti-epileptic drugs and anti-diabetic drugs. It is necessary to include the total drug influence coefficient of the user's medication status on folic acid activity into the influence coefficient set, so that the real activity data obtained subsequently includes consideration of the user's medication status.

[0178] In the method of this embodiment, when the user uses other drugs that affect folic acid activity, the total drug impact coefficient is calculated based on the dosage of each influencing drug and the time difference between the taking of the drug and the monitoring time, so that the total drug impact coefficient is highly consistent with the user's medication situation, so that when the user uses other drugs that affect folic acid activity, the real activity data taking the user's medication situation into consideration can be obtained later, which further makes the final judgment of the folic acid activity in the user's body more accurate and comprehensive.

[0179] In some embodiments, the influence weight of each influence coefficient in the influence coefficient set is determined according to the influence coefficient set; based on the externally reflected activity data, the real activity data of folic acid in the body of the user is determined according to the influence coefficient set, and calculated with reference to formula (7):

[0180] (7);

[0181] in, is the real activity data, is the number of influence coefficients in the influence coefficient set, For the activity data reflected externally, is the first The influence coefficient, The first The influence weight of an influence coefficient.

[0182] The influence weight of the influence coefficient may be the influence ratio data of the influence coefficient corresponding to different situations in the above embodiment on the overall folic acid activity of the user.

[0183] It should be noted that the influence weight of each influence coefficient in the influence coefficient set can be set by referring to the following weight ranking, taking the case listed in the above embodiment as an example:

[0184] First of all, the influence coefficient with the highest influence weight is the metabolic function influence coefficient. The overall function of the human body integrates the metabolic influence of various organs, so the weight accounts for the largest proportion.

[0185] The second is the liver function influence coefficient, because the liver has an important influence on the metabolism and storage of folic acid. Various enzymes in the liver can directly affect the activity and utilization of folic acid. The health of liver function directly affects the level and activity of folic acid.

[0186] Then there is the renal function influence coefficient. Because the kidneys play an important role in the excretion of folic acid, the quality of renal function will affect the clearance and stability level of folic acid. Kidney disease or damage may lead to abnormal folic acid levels.

[0187] Finally, there are the gastric function influence coefficient and the intestinal function influence coefficient. Since gastrointestinal absorption is the key channel for folic acid to enter the body, the weights of the gastric function influence coefficient and the intestinal function influence coefficient should be similar.

[0188] The method of this embodiment calculates the real activity data based on the activity data reflected externally according to the influence coefficient corresponding to the physical condition of the user and the influence weight corresponding to the influence coefficient, so that the real activity data highly conforms to the current physical condition of the user, thereby making the real activity data more representative in reflecting the overall folic acid activity in the body of the user, and providing an important data basis for subsequent judgment of the overall folic acid activity of the user.

[0189] In some embodiments, the standard metabolic rate is determined based on the basic information; the folic acid activity standard is determined based on the basic information and the standard metabolic rate; the folic acid activity standard is determined based on the basic information and the standard metabolic rate, and is calculated with reference to formula (8):

[0190] (8);

[0191] in, is the basic standard of folic acid activity, is the coefficient of relationship between standard metabolic rate and folic acid activity, is the standard metabolic rate; based on the basic standard of folic acid activity and the influence coefficient set, the final folic acid activity standard is calculated by formula (9):

[0192] (9);

[0193] in As the final folic acid activity standard, It is the basic standard of folic acid activity. The first The influence coefficient, The first The influence weight of an influence coefficient.

[0194] The standard metabolic rate may be the metabolic rate of a normal human body that coincides with the basic information of the user.

[0195] The relationship coefficient between the standard metabolic rate and folic acid activity can be obtained through historical data statistics.

[0196] The basic standard of folic acid activity may be folic acid activity data required by the human body at a standard metabolic rate.

[0197] The influence weight of each influence coefficient in the influence coefficient set may refer to the ranking and division of the influence weights in the aforementioned embodiment.

[0198] Specifically, when the user's body shows the conditions listed in the above embodiments, the folic acid activity standard in a normal human body cannot be used as a standard to measure whether the actual activity data in the user's body meets the standard. At this time, the influence coefficient corresponding to the user's physical condition should be included in the calculation of the final folic acid activity standard based on the folic acid activity basic standard to obtain a folic acid activity standard that meets the user's current physical condition.

[0199] The method of this embodiment calculates the final folic acid activity standard based on the influence coefficients in the influence coefficient set and the influence weights corresponding to each influence coefficient and based on the basic folic acid activity standard. This fully takes into account the fact that when the user has physical abnormalities, the standard for judging the activity of folic acid in his body should also be adjusted accordingly, so that the adjusted final folic acid activity standard is highly consistent with the user's current physical condition, thereby making the judgment of the user's overall folic acid activity more accurate and comprehensive.

[0200] In some embodiments, if the folic acid activity index in the body of the user does not meet the standard, the activity difference value is determined based on the actual activity data and the final folic acid activity standard; the dosage of the high-activity folic acid drug taken by the user before monitoring is obtained, and the drug utilization rate of the user is determined based on the dosage of the high-activity folic acid drug and the actual activity data; the drug utilization rate of the user is determined based on the dosage of the high-activity folic acid drug and the actual activity data, and is calculated with reference to formula (10):

[0201] (10);

[0202] in, is the drug utilization rate, is the real activity data, is the dose of the high-activity folic acid drug taken by the user before monitoring; the supplementary drug dose is determined based on the activity difference value and the drug utilization rate; the supplementary drug dose is determined based on the activity difference value and the drug utilization rate, and is calculated with reference to formula (11):

[0203] (11);

[0204] in, To supplement the dosage of the drug, is the activity difference value, It is the drug utilization rate; according to the supplementary drug dosage, the drug users are given drug supplements.

[0205] The activity difference value can be the difference between the actual activity data and the final folate activity standard.

[0206] The dosage of the highly active folic acid drug taken by the user before monitoring can be obtained from the medication record.

[0207] Drug utilization rate can be the proportion of folic acid that can be absorbed by taking a unit dose of high-activity folic acid drug under the user's current physical condition.

[0208] The dosage of the supplementary drug can be the dosage of the high folate activity drug required to supplement the overall folate activity index in the body of the user to reach the final folate activity standard.

[0209] Specifically, if, through the aforementioned monitoring and judgment process, it is found that the folic acid activity index in the body of the drug user is not up to standard, it is necessary to calculate the drug dosage that the drug user needs to supplement based on the difference between the actual activity data and the final folic acid activity standard and the drug utilization rate of the drug user, so that the folic acid activity in the body of the drug user reaches the standard and the treatment effect of the drug user is guaranteed.

[0210] In the method of this embodiment, when the folic acid activity index in the body of the drug user does not meet the standard, the dosage of high-folate activity drug that the drug user needs to supplement is obtained based on the difference between the actual activity data and the final folic acid activity standard, combined with the drug utilization rate of the drug user, so that the folic acid activity in the body of the drug user meets the standard and the treatment effect of the drug user is guaranteed.

Claims

1. A method for monitoring the survival of highly active folic acid, characterized in that: include: Acquire the physical condition information of the medication user, and determine the influence coefficient set of the current physical condition of the medication user on the folic acid activity according to the physical condition information; the physical condition information includes at least one of information for characterizing liver function, information for characterizing kidney function, information for characterizing stomach function, information for characterizing intestinal function, information for characterizing metabolic function, and medication information; Acquiring the blood test data of the user, determining the outwardly reflected activity data of folic acid in the user, and determining the real activity data of folic acid in the user based on the outwardly reflected activity data and the influence coefficient set; Acquiring basic information of the drug user, determining a basic standard of folic acid activity based on the basic information, and determining a final folic acid activity standard of the drug user based on the basic standard of folic acid activity and the influence coefficient set; Comparing the actual activity data with the final folic acid activity standard, and judging whether the difference between the actual activity data and the final folic acid activity standard is within a preset difference range according to the comparison result, and if so, determining that the folic acid activity index in the user's body has reached the standard; The determining of the real activity data of folic acid in the body of the user based on the outwardly reflected activity data and according to the influence coefficient set includes: Determining, according to the influence coefficient set, an influence weight of each influence coefficient in the influence coefficient set; Based on the outwardly reflected activity data, according to the influence coefficient set, the real activity data of folic acid in the body of the user is determined, and calculated according to the following formula: ； in, is the real activity data, is the number of influence coefficients in the influence coefficient set, For the said outwardly reflecting active data, is the first The influence coefficient, The first The influence weight of each influence coefficient; The step of determining the basic standard of folic acid activity based on the basic information, and determining the final folic acid activity standard of the user based on the basic standard of folic acid activity and the influence coefficient includes: Determining a standard metabolic rate based on the basic information; Determining the folic acid activity standard according to the basic information and the standard metabolic rate; The folic acid activity standard is determined based on the basic information and the standard metabolic rate, and is calculated according to the following formula: ； in, is the basic standard of folic acid activity, is the coefficient of relationship between standard metabolic rate and folic acid activity, is the standard metabolic rate; Based on the basic folate activity standard and according to the influence coefficient set, the final folate activity standard is calculated by the following formula: ； in is the final folic acid activity standard, is the basic standard of folic acid activity, is the first An influence coefficient.

2. The method according to claim 1, characterized in that The physical condition information includes AST value and ALT value, and determining the influence coefficient set of the current physical condition of the user on folic acid activity based on the physical condition information includes: The AST value and the ALT value are compared with a preset normal liver function data range, and if at least one of the AST value and the ALT value is outside the preset normal liver function data range, the liver function influence coefficient of the user's liver function on the folic acid activity is included in the influence coefficient set; According to the AST value and the ALT value, the liver function influence coefficient is calculated according to the following formula: ； in, is the liver function influence coefficient, The influence ratio of the preset AST value is: The influence ratio of the preset ALT value.

3. The method according to claim 2, characterized in that The physical condition information also includes a GFR value and a UAE value. The determining of the influence coefficient set of the current physical condition of the user on the folic acid activity based on the physical condition information includes: The GFR value and the UAE value are compared with a preset normal renal function data range. If at least one of the GFR value and the UAE value is outside the preset normal renal function data range, the renal function influence coefficient of the user's renal function on the folic acid activity is included in the influence coefficient set as the influence coefficient; According to the GFR value and the UAE value, the renal function influence coefficient is calculated according to the following formula: ； in, is the renal function influence coefficient, The influence ratio of preset GFR value is The impact ratio of the preset UAE value.

4. The method according to claim 3, characterized in that The physical condition information also includes a GAC ​​value and a GAPH value. The determination of the influence coefficient set of the current physical condition of the user on the folic acid activity based on the physical condition information includes: The GAC value and the GAPH value are compared with a preset normal gastric function data range, and if at least one of the GAC value and the GAPH value is outside the preset normal gastric function data range, the gastric function influence coefficient of the gastric function of the user on the folic acid activity is included in the influence coefficient set as the influence coefficient; According to the GAC value and the GAPH value, the gastric function influence coefficient is calculated according to the following formula: ； in, is the gastric function influence coefficient, The impact ratio of the preset GAC value is: It is the influence ratio of preset GAPH value.

5. The method according to claim 4, characterized in that The physical condition information also includes a PDA value and an IPH value. The determination of the influence coefficient set of the current physical condition of the user on the folic acid activity based on the physical condition information includes: The PDA value and the IPH value are compared with a preset normal intestinal function data range. If at least one of the PDA value and the IPH value is outside the preset normal intestinal function data range, the intestinal function influence coefficient of the intestinal function of the user on the folic acid activity is included in the influence coefficient set as the influence coefficient; According to the PDA value and the IPH value, the intestinal function influence coefficient is calculated according to the following formula: ； in, is the intestinal function influence coefficient, is the influence ratio of preset PDA value, It is the impact ratio of preset IPH value.

6. The method according to claim 5, characterized in that The physical condition information also includes a BMR value and a UAL value. The determination of the influence coefficient set of the current physical condition of the user on the folic acid activity based on the physical condition information includes: The BMR value and the UAL value are compared with a preset normal metabolic function data range. If at least one of the BMR value and the UAL value is outside the preset normal metabolic function data range, the metabolic function influence coefficient of the user's metabolic function on the folic acid activity is included in the influence coefficient set as the influence coefficient; According to the BMR value and the UAL value, the metabolic function influence coefficient is calculated according to the following formula: ； in, is the metabolic function influence coefficient, The influence ratio of preset BMR value, The impact ratio of the preset UAL value.

7. The method according to claim 6, characterized in that The physical condition information also includes the medical history information of the medication user. The determination of the influence coefficient set of the current physical condition of the medication user on the folic acid activity based on the physical condition information includes: Determining the long-term medication information of the medication user according to the medical history information of the medication user; Matching the long-term medication information with the drug data affecting folic acid activity in the preset drug impact data set, and if the match is successful, determining the influencing drug information according to the matching result, and including the total drug impact coefficient of the user's medication situation on the folic acid activity into the impact coefficient set; Determine, based on the influencing drug information, the time difference between the dosage and the taking time of each influencing drug and the monitoring time; Determining the total drug impact coefficient according to the dosage and the time difference; The total drug impact coefficient is determined based on the dosage and the time difference and is calculated according to the following formula: ； in, is the total drug effect coefficient, For the the dose of the drug for the effect, is the time difference.

8. The method according to claim 1, characterized in that: The method further comprises: If the folic acid activity index in the user does not meet the standard, determining the activity difference value according to the actual activity data and the final folic acid activity standard; Obtaining the dosage of the high-activity folic acid drug taken by the user before monitoring, and determining the drug utilization rate of the user according to the dosage of the high-activity folic acid drug and the real activity data; The drug utilization rate of the user is determined based on the dosage of the high-activity folic acid drug and the real activity data, and is calculated according to the following formula: ； in, is the drug utilization rate, is the real activity data, The dosage of the high-activity folic acid drug taken by the user before monitoring; determining a supplemental drug dosage according to the activity difference value and the drug utilization rate; The supplementary drug dosage is determined based on the activity difference value and the drug utilization rate, and is calculated according to the following formula: ； in, For the supplementary drug dosage, is the activity difference value, is the utilization rate of the drug; The user is given drug supplement according to the supplementary drug dosage.

Images